The board of Muscular Dystrophy NSW provides direction, support and governance to Muscular Dystrophy NSW. It currently has 6 full board meetings per year. Board sub-committees provide extra focus and skills to Muscular Dystrophy NSW and consist of the following:

Each Director will serve on at least two Board Committees including at least one of the major Committees (being Client Services, Finance or Marketing & Fundraising)

Click here for more information about Muscular Dystrophy Association of NSW Board Charter.


The board consists of the following members:

Anthony Ball – President

Anthony has been ClubsNSW CEO since 2010 and is also CEO of ClubKENO Holdings and the Executive Director of ClubsAustralia, the national umbrella association for clubs.
Anthony has been with ClubsNSW since 1999 and prior to his appointment as CEO, he was Executive Manager for Policy and Government and was responsible for state and national based industry advocacy. He has a Bachelor of Economics from the Australian National University, a Certificate of Public Affairs from the University of Sydney and is a graduate of the American University’s Public Affairs and Advocacy Institute in Washington DC.

Shannon Finch, ANU BA (Hons) LLB (Hons), MAICD – Vice President

Shannon Finch is a corporate lawyer with over 27 years experience, including a specialty in corporate governance. She is a senior partner of a major global corporate law firm, Jones Day.   Shannon was previously a partner at King & Wood Mallesons, and head of its operations in Sydney, as well as leading practice teams within the firm.  Prior to joining Mallesons, she worked with the Commonwealth Attorney-General’s department.  Shannon is the national Chairman of the Corporations Committee of the Law Council of Australia, and is a guest-lecturer on securities and disclosure laws at the University of Sydney and University of NSW. She is a member of AICD, FINSIA and Women in Banking and Finance, and a sponsor of Bell Shakespeare and Sydney Dance Company.  Shannon has been a director of MDNSW since 2012 and is also non-executive director of ParaQuad NSW (a not-for-profit social enterprise).


Richard Arnheim BCom – Treasurer

Member Institute of Chartered Accountants in Australia, Fellow Financial Planning Association of Australia, Certified Financial Planner,  Diploma of Financial Planning – Deakin University, Principal  Arnheim Gillard Financial Consultants 1986 – 2008 and principal Arnheim Hornbrook Chartered Accountants 1986 – 2000, Authorised Representative and principal advisor of Shadforth Financial Group 2008- present.

Rick Arnheim from  early teens has had a neuromuscular disease broadly similar to Limb Girdle Muscular Dystrophy.


Clinical A/Professor Kristi Jones MBBS, FRACP, CG(HGSA), PhD – Medical Director

Kristi Jones is a Paediatrician and Clinical Geneticist with an interest in genetic neuromuscular conditions who heads the clinical neuromuscular service at Children’s Hospital at Westmead.
Kristi graduated from The University of Sydney in 1990. Her post-graduate qualifications include: Fellowship of the Royal Australasian College of Physicians, Clinical Geneticist of the Human Genetics Society of Australasia (HGSA), and a Doctorate (PhD).
She also consults at Genea, seeing couples going through their preimplantation genetic diagnosis (PGD) program.
Kristi’s current research interests stem from her PhD, and focus on the clinical and genetic diagnosis of muscular dystrophies and therapeutic trials for genetic muscle disease. She heads the Clinical Trials Unit within the Institute for Neuroscience and Muscle Research at Childrens Hospital at Westmead.
She is a Clinical Associate Professor in the Discipline of Paediatrics and Child Health, Sydney Medical School, at the University of Sydney, lecturing and teaching in paediatrics and genetics.
Kristi is a member of the Human Genetics Society of Australasia, and the Australasian Association of Clinical Geneticists.


Kim Brislane

Kim Brislane has specialised in the Not for Profit sector  for over 20 years honing her skills as the National CEO of The Duke of Edinburgh’s Award in Australia from 2007 – 2012. Kim has also worked with the Coca Cola Foundation, The Sydney Children’s Hospital Foundation, Odyssey House, The International Award for Young People as well as Flight Centre globally and Porsche.  In 2011 Kim was one of three Not-for-Profit CEOs awarded a Harvard Business School scholarship held in Sydney. She sits on two other Boards focusing on Women’s Health and Legal Aid for the wider Blue Mountains and regional community and is an Ambassador of The Duke of Edinburgh’s Award in Australia.


Christina Liang MBBS, BSc(Med), FRACP

Christina is a staff specialist in neurology at Royal North Shore Hospital. She graduated from UNSW in 2002 and completed her training at Westmead and Royal North Shore Hospitals. She cares for adolescents and adults with various neuromuscular and neurogentic conditions through the Neuromuscular/ Transition and Neurogenetics Clinics. She is currently completing her doctoral studies in the management of adult patients with mitochondrial diseases, and is involved in international clinical trial and research.


David Kay

David has more than 12 years’ experience working across the human services sectors in Australia and New Zealand. David’s main focus is on the ageing and disability sectors, and advises both Commonwealth and State/Territory government and large not-for-profit organisations on ageing and disability sector reform, program review and evaluation, strategic and operational planning and operational improvement. Most recently, David has led a number of engagements relating to the development and implementation of the National Disability Insurance Scheme (NDIS).



Nathan Teong BCom, GradDipAppFin

Nathan has worked in the Funds Management industry for 20 years, working in various roles across the Accounting, Investment Operations, Client Services and Performance Reporting teams. He is currently Performance Reporting Team Leader at Magellan Asset Management, a leading global equity and global listed infrastructure investment manager. He holds a Bachelor of Commerce from The University of Newcastle and a Graduate Diploma of Applied Finance from Kaplan Professional.

Nathan’s young son, George, was diagnosed with a congenital myopathy at 4 months of age.


Stuart Uhlhorn

Stuart is experienced, independent commercially qualified company director with extensive business experience gained both in Australia and overseas. Industries worked in have included; Aged care sector, Oil and Gas, Insurance and finance, Property Investment and Management, Industrial services and Rail engineering services.

He has worked on numerous commercial Joint Venture and Not for Profit Boards including UnitingCare Ageing (NSW.ACT), which he chaired from 2011 to 2014, and UnitingCare. He is a Fellow of the AICD and a Fellow of CPA Australia and has an Economics degree and a post graduate diploma in Financial Management.


Michelle Ball

Michelle is Senior Vice President and Head of Human Resources for Bank of America Merrill Lynch and a member of the Executive Committee for Australia. In addition, Michelle is the Regional Learning, Leadership Development and Diversity & Inclusion Executive covering 12 countries across Asia Pacific.
Previously, Michelle held several senior regional European and Emerging Market HR roles in both the Banking and Pharmaceutical industries. Before moving into HR, Michelle held a variety of roles within sales and marketing for Johnson and Johnson in the United Kingdom and Australia. Michelle is also a member of the Australia Institute of Company Directors. Michelle qualified as a Dietitian with the University of Newcastle and gained experience as a clinical and community Dietitian. Michelle is also an AOEC accredited Executive Coach.

Michelle is a mother of little boy with a rare form of Congenital Muscular Dystrophy and was one of the leaders of a crowd fund campaign called Beat4life which connected people globally to fund critical research in the US. Michelle has attended several international conferences to help advocate for the required research pathways and remains very connected to key scientists, clinicians and patient groups globally, all with a united vision to make strides forward in research for suitable treatments and a cure.